Exvastat

About:

Exvastat is an innovative, preclinical-stage pharmaceutical company.

Twitter/X: exvastat

Top Investors: Cambridge Innovation Capital, Innovative Medicines Initiative

Description:

Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.

Total Funding Amount:

3.6M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2016-01-01

Contact Email:

info(AT)exvastat.com

Founders:

Andrew McElroy, David Cavalla

Number of Employees:

1-10

Last Funding Date:

2020-05-15

IPO Status:

Private

Industries: